These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8389501)

  • 1. Relation of elastosis to biochemical and immunohistochemical steroid receptor findings, Ki-67 and epidermal growth factor receptor (EGFR) immunostaining in invasive ductal breast cancer.
    Remmele W; Dietz M; Schmidt F; Schicketanz KH
    Virchows Arch A Pathol Anat Histopathol; 1993; 422(4):319-26. PubMed ID: 8389501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
    Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
    Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunocytochemistry and in situ hybridisation of epidermal growth factor receptor and relation to prognostic factors in breast cancer.
    Bilous M; Milliken J; Mathijs JM
    Eur J Cancer; 1992; 28A(6-7):1033-7. PubMed ID: 1320909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer.
    Ioachim E; Kamina S; Athanassiadou S; Agnantis NJ
    Anticancer Res; 1996; 16(5B):3141-7. PubMed ID: 8920782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In situ distribution of oncogene products and growth factor receptors in breast carcinoma: c-erbB-2 oncoprotein, EGFr, and PDGFr-beta-subunit.
    Kommoss F; Colley M; Hart CE; Franklin WA
    Mol Cell Probes; 1990 Feb; 4(1):11-23. PubMed ID: 1969111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
    Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
    Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.
    Poller DN; Hutchings CE; Galea M; Bell JA; Nicholson RA; Elston CW; Blamey RW; Ellis IO
    Br J Cancer; 1992 Sep; 66(3):583-8. PubMed ID: 1355662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCNA/cyclin expression in breast carcinomas: its relationships with Ki-67, ER, PgR immunostainings and clinico-pathologic aspects.
    Tuccari G; Rizzo A; Muscarà M; Giuffrè G; Barresi G
    Pathologica; 1993; 85(1095):47-55. PubMed ID: 8100059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis.
    Sahin AA; Ro J; Ro JY; Blick MB; el-Naggar AK; Ordonez NG; Fritsche HA; Smith TL; Hortobagyi GN; Ayala AG
    Cancer; 1991 Aug; 68(3):549-57. PubMed ID: 1648433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there 'progression through grade' in ductal invasive breast cancer?
    Schymik B; Buerger H; Krämer A; Voss U; van der Groep P; Meinerz W; van Diest PJ; Korsching E
    Breast Cancer Res Treat; 2012 Oct; 135(3):693-703. PubMed ID: 22886478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast.
    Lebeau A; Unholzer A; Amann G; Kronawitter M; Bauerfeind I; Sendelhofert A; Iff A; Löhrs U
    Breast Cancer Res Treat; 2003 May; 79(2):187-98. PubMed ID: 12825853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of c-erbB3 protein in primary breast carcinomas.
    Naidu R; Yadav M; Nair S; Kutty MK
    Br J Cancer; 1998 Nov; 78(10):1385-90. PubMed ID: 9823984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of P-cadherin, but not E-cadherin or N-cadherin, relates to pathological and functional differentiation of breast carcinomas.
    Kovács A; Dhillon J; Walker RA
    Mol Pathol; 2003 Dec; 56(6):318-22. PubMed ID: 14645693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proliferating cell nuclear antigen immunostaining in breast cancer and its relation to prognosis.
    Narita T; Funahashi H; Satoh Y; Takagi H
    Jpn J Clin Oncol; 1993 Feb; 23(1):20-5. PubMed ID: 8096256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer.
    Gasparini G; Bevilacqua P; Pozza F; Meli S; Boracchi P; Marubini E; Sainsbury JR
    Br J Cancer; 1992 Nov; 66(5):970-6. PubMed ID: 1419645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast.
    Walker RA; Dearing SJ
    Eur J Cancer; 1992; 28(2-3):641-4. PubMed ID: 1317202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histological differentiation in human breast cancer is related to steroid receptors and stromal elastosis.
    Rolland PH; Jacquemier J; Martin PM
    Cancer Chemother Pharmacol; 1980; 5(2):73-7. PubMed ID: 7471317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptors in human breast cancer: a plea for standardisation of assay methodology.
    Koenders PG; Faverly D; Beex LV; Bruggink ED; Kienhuis CB; Benraad TJ
    Eur J Cancer; 1992; 28(2-3):693-7. PubMed ID: 1591096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas.
    Haerslev T; Jacobsen GK; Zedeler K
    Breast Cancer Res Treat; 1996; 37(2):101-13. PubMed ID: 8750578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.